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Chronic Myeloid Leukemia (CML) represents a paradigm for the wider cancer field. Despite the fact that
tyrosine kinase inhibitors have established targetedmolecular therapy inCML, patients often face the risk of
developing drug resistance, caused by mutations and/or activation of alternative cellular pathways. To
optimize drug development, one needs to systematically test all possible combinations of drug targets within
the genetic network that regulates the disease. The BioModelAnalyzer (BMA) is a user-friendly
computational tool that allows us to do exactly that. We used BMA to build a CML network-model
composed of 54 nodes linked by 104 interactions that encapsulates experimental data collected from 160
publications. While previous studies were limited by their focus on a single pathway or cellular process, our
executable model allowed us to probe dynamic interactions between multiple pathways and cellular
outcomes, suggest new combinatorial therapeutic targets, and highlight previously unexplored sensitivities
to Interleukin-3.
C
ancer is recognized as a highly complex aberrant cellular state where initiating mutations impact either
directly or indirectly on a multitude of regulatory pathways. Chronic Myeloid Leukaemia (CML) repre-
sents a paradigm for cancer, both in terms of understanding the nature of the molecular lesion as well as
the ability to develop targeted therapies. Whilst the development of targeted drugs has revolutionized the
treatment of CML patients, drug resistance is an inevitable consequence of this therapeutic approach. Hence,
devising strategies to delay or overcome drug resistance becomes a major challenge, calling for systematic
screening of multiple drug targets and their combinations.
Traditionally, biological and medical research has focused on the study of individual genes and proteins in
isolation from other elements that comprise the entire system in which they interact and function. While this
reductionist approach has been effective in elucidating specific characteristics of particular biological processes,
scientific discovery is increasingly limited rather than guided by reductionist principles because the functionality
of biomolecules critically depends on interactions with many other biomolecules1. Importantly, innovations in
high-throughput data generation and automation have set the scene for more integrative approaches2. No less
important than the generation of data describing biological functional relationships is our ability to interpret this
data. Mechanistic diagrams have been commonplace in biology, but these static representations fail to capture
variations in relationships over time and the sheer scale of the systems represented often proves these to be too
unwieldy. Modeling, and especially computational modeling, has thus become a powerful tool in this endeavor.
While mathematical models can be simulated through translating mathematics to algorithms, computational
models are immediately executable, allowing for larger-scale simulation of biological systems3. In addition,
analysis techniques common in computer science and formal verification can be directly applied to such models.
One such technique, model checking, involves analyzing all possible executions of themodel, but without actually
executing all these possibilities4. This analysis allows for rapid and thorough comparison of the computational
model with experimental data; a cyclic process is thus able to be realized in which a draft model is composed,
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model checking is applied, the model is assessed to see if it fits with
experimental data, and a revised model is produced. Boolean net-
works, pioneered by Kauffman as a model for genetic regulatory
networks, have already been used in interpretation of large data sets
as well as for drug discovery5–7. In this formalism, relationships are
represented in a dynamic network with discrete time steps. Genes in
this type of networks, represented by nodes, can have two states
(hence a Boolean network) and edges are directed and may be activ-
ating or inhibitory.
In this study, we use the Qualitative Networks (QNs) generaliza-
tion of Boolean Networks8 to model the gene regulatory network of
CML. CML has been extensively mathematically modeled on a cell
population level, but not at the level of a genetic network9–11. CML
represents an idealmodel for the genetic study ofmalignancy, since it
is linked to a consistent molecular event, the translocation between
chromosomes 9 and 22, which gives rise to the so-called Philadelphia
chromosome expressing the oncogenic fusion protein Bcr-Abl. If
untreated, CML has a well-defined and mostly-uniform progression
from the relatively manageable chronic phase (CP) to its terminal
blast crisis (BC) phase12. In this work we first integrated the current
body of knowledge on the molecular pathways involved in CML into
a gene regulatory network via manual inspection of the relevant
literature. We then constructed a Qualitative Network executable
model of CML progression using the BMA tool (freely available at
http://biomodelanalyzer.research.microsoft.com/) based on the
CML network curated from the literature. The analysis of our
CML network-model had generated novel hypotheses for network
sensitivity via in silico removals and knock-outs of combinations of
cytokines, genes, and genetic interactions (Figure 1). Furthermore,
themodel suggested new combinatorial therapeutic targets and high-
lighted unknown sensitivities to IL-3. Further enhanced by the user-
friendly interface of BMA, this study serves as a proof of concept for
the wider community on how the implementation of state of the art
computational modeling can become a routine procedure for the
whole of the modern biomedical research community.
Methods
Qualitative Networks. Qualitative networks (QN) extend Boolean networks by
allowing variables to range over larger discrete domains and replacing Boolean
functions by algebraic functions8. Intuitively, a Qualitative Network associates a
discrete variable with every substance the model follows. The variable ranges over a
small discrete domain where values represent expression levels of the substance such
as {05 off, 15 low, 25 medium, 35 high}. For every substance, a target function
reads the values of other substances that affect it. The target function sets a value to
which the substance should get to eventually. The substance changes gradually to
attain this target.
More formally, a Qualitative Network is defined as follows. A Qualitative Network
isQ5 (V,T,N) consists of a set of variablesV5 {v1,…, vn} ranging over {0,…,N} and
a set of target functions T5 {T1,…,Tn}. A state of the network is s:VR {0,…,N}, i.e.,
a valuation for all the variables in Q. A target function Ti associates with a state s a
value in {0, …, N}, the value towards which vi should move from state s.
A Qualitative Network gives rise to a transition system between its states. As
explained, the values of substances/variables change by pursuing their targets
gradually, i.e., they change by at most 1 in every transition. Thus, every state s 5
{d1,…, dn}, where the value of vi is di, has a successor s95 T(s), where s9(vi) is defined
as follows:
di{1 if Ti sð Þvdi and diw0
diz1 if Ti sð Þwdi and divN
di if
1: Ti sð Þ~di
2: Ti sð Þvdi and di~0
3: Ti sð Þwdi and di~N
8><
>>:
Notice that all variables are updated simultaneously. A discrete change in the value
of a variable corresponds to a number of simultaneous molecular events over a period
of time, and as such non-deterministic events are not considered. Target functions
default to the difference between the average of the activator nodes and the average of
the inhibitor nodes unless explicitly altered.
It follows that a Qualitative Network defines a finite state transition system where
state changes are deterministic. Then every execution of a Qualitative Network ends
in a cycle of states that are visited infinitely often. We say that a state is recurring if it
appears in an execution that starts from itself. That is, if for some finite number of
applications of T, we have s5 Ti(s). A network is stabilizing if there is a unique state s
such that s 5T(s) and no other state is recurring.
The BioModelAnalyzer (BMA) Platform. BMA is a graphical tool for the
construction and analysis of biological models in the form of Qualitative Networks
Figure 1 | BMA workflow. Genetic interactions curated from the literature are used to build the Qualitative Network in the BMA, whilst the results of
known experimental mutations are used to build a ‘‘specification’’ which explicitly links the cell fate to a change in the system. By testing themodel in the
BMA and comparing the results to the specification, the model is iteratively refined until it matches the specification. Once a working model has been
defined, further in silico experiments can be performed to explore new avenues.
www.nature.com/scientificreports
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(QNs). It uses visual notations to implicitly define QNs, and has been designed with
and for users who have no experience with computational modeling and analysis.
Models are built up on a gridded canvas, onto which cells, cell elements, and
connections between them can be dragged and dropped. Modeling starts by adding
cells onto the grid. Though cells do not have a functional role in the formal
mathematical definition of the model they do make the model more visually
appealing and make it easier to design models that have repeating motifs in them (by
copying and pasting whole cells). Then proteins or genes are added to the cells, each
corresponding to a variable in the underlying QN. There are two types of proteins:
membrane bound receptors and standalone proteins, which lie inside the cell.
Proteins can be placed inside and outside cells, and can be set to constant values.
Activation (arrows) and inhibition (bar arrows) influences can be drawn between
proteins or genes (Supplemental Figure 2a).
The drawing created using the graphical user interface gives rise to an underlying
QN. Initially, all values of this QN are default with the default range of {0, 1} per every
protein, and the default target function of ‘‘average difference’’ (i.e., representing the
average of activation influences minus the average of inhibition influences), as illu-
strated in Supplemental Figure 2B. Next, the QN can be further specialized using
simple drop-down menus where protein names, ranges, and target functions can be
defined. Target functions can be composed using standard algebraic and numerical
operations (such as addition, subtraction, mulitplication, division, minimum, max-
imum, average) and by referring to constants or other proteins that are affecting this
protein (i.e., having an arrow or bar-arrow to it) using the keyword var(protein_
name), thus enabling the straightforward encoding of complex dependencies between
the proteins.
BMA currently supports both simulation and stabilization analysis. In a simulation
the tool shows an execution of the network starting from a given valuation for the
proteins. It is possible to randomize the initial state or choose it (or some of it)
directly. A simulation can be complemented by a graph highlighting some of the
proteins and drawing their changes over time. Stabilization analysis in BMA is based
on the algorithm in Ref. 13. The tool tries to prove that the network does stabilize. If it
succeeds, it shows the values onwhich each of the proteins stabilizes. If the tool cannot
establish stabilization, it tries to find executions that will show that the network does
not stabilize: either two different executions leading to two different loops or an
execution ending in a loop that is larger than 1. The result of stabilization analysis is
displayed on the main graph of the network. In case of instability an execution of the
model exhibiting the instability is shown.
Results
Construction of a quantitative networkmodel for CML.Based on a
manual curation of 160 publications, we constructed a QN model
representing a generally accepted canonical set of 37 genes, 6
receptors, and 2 cytokines involved in CML containing a total of
54 nodes (including 4 ligands and 5 cell behaviors) linked by 81
interactions (Supplemental Tables 1, 2, and 3). Each terminally
downstream node, defined as those nodes without other nodes
further downstream of them, was then categorized into either
activating or inhibiting one of five cell fates or behaviors:
proliferation, self-renewal capacity, growth arrest, proper/correct
differentiation, and apoptosis. Intuitively, the level of proliferation,
self-renewal, growth arrest, differentiation and apoptosis
corresponds to the existence of markers in the cell that are linked
to these behaviors. Iterative modification of the target functions of
each node was then performed to ensure that values of individual
genes and cell behaviors were in correspondence with actual
experimental data (Figure 2).
All nodes were assigned a range of 0 to 2. The decision to restrict
the range to these values was made based on the literature survey.
Based on the manual curation of the literature, the values represent
the following. For genes, 0 represents low or no activity, 1 represents
moderate activity, and 2 represents high activity. For the cell fates, 0,
1, and 2 represent absence, moderate amounts of, and high levels of
Figure 2 | Model of genes, external factors, receptors, and cell behaviors involved in CML. Network visualization through the GUI interface of BMA.
External cell factors, receptors, and internal genes are depicted in grey, green, and red respectively.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 8190 | DOI: 10.1038/srep08190 3
proliferation, self-renewal capacity, and apoptosis respectively. As
growth arrest and correct differentiation are conditions that can be
represented by a binary variable, a value of 0 corresponds to absence
of the cell property, while a value of 1 corresponds to presence of the
property. For consistency, the ranges of these two cell fates are kept at
0 to 2, but a value of 2 is not reached in any of the in silico experiments
or runs of the model. The default target function of ‘‘average differ-
ence’’ was assigned to most genes with the modification of rounding
the result to the nearest integer instead of rounding to the integer
below. For genes with only negative influence, we set their target
function to a maximum attainable level (could be 1 or 2) minus
the average of the incoming negative influences. This corresponds
to being constitutively active unless some inhibition is present. As an
additional example, the target function of b-catenin is set to the level
of Bcr-Abl1 1 minus the sum of Axin2 and Gsk3B, that is var(Bcr-
Abl) 1 1-var(Axin2)-var(Gsk3B). From biological literature it is
known that that Axin2 is negative regulator of canonical Wnt/TCF
signalling by enhancing formation of the b-catenin destruction com-
plex14. Also GSK3B phosphorylates b-catenin on the N-terminal
Thr41, Ser37, and Ser33 residues, and phosphorylated b-catenin is
ubiquitinated by the F-box-containing protein b-TrCP ubiquitin E3
ligase to be degraded by the proteasome.
The non-disease control state was modeled by setting the target
function of Bcr-Abl in the model to 0. The CP disease state was
modeled by setting the initial value of Bcr-Abl to 2, and setting the
initial value of b-catenin to 0, as this pathway is described in the
literature as not being activated until BC. The BC disease state was
modeled with the initial value of Bcr-Abl at 2, and b-catenin
unrestricted.
The model was initially checked without any knock-outs or mod-
ifications, and with all factors at the moderate level, 1. The baseline
resultant cell behavior levels were as follows: forWT, growth arrest at
0, self-renewal capacity at 1, apoptosis at 1, proliferation at 1, and
correct differentiation at 1; for CP CML, growth arrest at 0, self-
renewal capacity at 1, apoptosis at 0, proliferation at 2, and correct
differentiation at 0; for BC CML, growth arrest at 0, self-renewal
capacity at 2, apoptosis at 0, proliferation at 2, and correct differenti-
ation at 0. The resultant cell behaviors therefore correlated well with
the known biology of CML with a gradual increase of self-renewal
capacity and proliferation accompanied by a simultaneous decrease
in apoptosis during the progression from wild type, to chronic phase
to blast crisis12.
A 54-node executable model of CML replicates experimental
results found in the literature. We next evaluated the accuracy of
the 54 node/81 edge network model of CML described above by
replicating in silico a sample of previous experiments found in
literature that were not used to construct or refine the model
(Table 1). In six out of seven cases, the model accurately and
directly recapitulated the experimental results found in literature.
For instance, Sonoyama et al. observed that expression of a single
dominant negative form of RAS, STAT5 or PI3K did not induce
apoptosis in K562 cells, but expression of combinations of these
proteins resulted in caspase-3 activation as measured by FACS15.
Table 1 | List of experiments verified through the model. Summary of experimental conclusions are given in ‘‘Conclusion’’, and in silico
results are given in ‘‘Model Results’’
in silico Experimental Details Conclusion Source Model Results
From base CML conditions, set any
2 of the following 3 (RAS, PI3K,
or STAT5) to 0. Observe Apoptosis.
2 out of 3 of the following
genes need to be active,
or else apoptosis occurs
in CML cells: RAS, PI3K,
or STAT5.
Sonoyama 2002 Apoptosis increases from 0 to 1 with the
removal of more than any one of the three
genes.
From base CPCML conditions, set all
factors (Wnt,VEGF, EPO, IL3, IL6, GH) to 0.
From base BCCML conditions, set all
factors to 0. Study HPNRK
knockout behavior.
HPNRK activation via ERK
in BC and CP cell lines supports
cytokine independent
proliferation, though
knock outs reduce cytokine
dependent proliferation.
Notari 2006 In the presence of cytokines, both CP and
BC CML show reduced proliferation (2 to
1) in the presence of a HPNRK knock out.
In the absence of cytokines, knock outs
have no effect.
From base CPCML conditions,
set constant of Bcr-Abl to 1 instead of 2.
Increase EPO to 2. Observe apoptosis.
EPO overcomes apoptosis
induced by Imatinib.
Uchida 2004 Apoptosis cycles between 0 and 1 after
EPO is raised from 1 to 2.
From base CPCML conditions,
set constant of Bcr-Abl to 1 instead of 2.
Observe proliferation and apoptosis.
From base BCCML conditions,
set constant of Bcr-Abl to 1 instead of 2.
Observe proliferation and apoptosis.
Imatinib reduces proliferation
abnormally upregulated
in CML progenitors, and
non-specifically
induces apoptosis.
Holtz 2002 Reducing Bcr-Abl levels to 1 from 2 in the
CPCML and BCCML states lowers
proliferation from 2 to 1, and increases
apoptosis from 0 to oscillating between 0
and 1.
From base CPCML conditions, set IL3 to 0.
Observe proliferation. From base BCCML
conditions, set IL3 to 0.
Observe proliferation.
IL3 upregulation induces
factor independent growth
in leukemic cells.
Holyoake 2001 Reducing IL3 from 2 to 0 results in
proliferation going from 2 to 1 in CPCML
and BCCML states.
From base CPCML conditions,
set Bcl-XL to 0. Observe apoptosis.
From base CPCML conditions,
set Bcl-XL to 1. Observe apoptosis.
Bcl-XL supression induces
apoptosis in CML cells.
Oetzel 2000,
Horita 2000.
Apoptosis increases from 0 to 1 in both
CPCML and BCCML states after reducing
Bcl-XL to 0.
From base CPCML conditions,
set all factors to 0. Observe
proliferation and self-renewal.
From base BCCML conditions, set all factors
to 0. Observe proliferation and self-renewal.
Bcr-Abl conveys the ability
for CML cells to have
factor-independent growth
Hariharan 1988 Proliferation and Self-Renewal capacity
remain at 1 in CPCML and at 1 and 2 in
BCCML even with removal of all factor
input from BCCML state.
www.nature.com/scientificreports
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In the in silico experiment, the same result is observed: setting the
target function of one of RAS, STAT5, or PI3K does not result in an
increase of the ‘‘apoptosis’’ cell fate from its base level of 0, but setting
the target function of any two of the genes results in an increase from
0 to 1. Holtz et al. observed that treatment of both CML and normal
primitive progenitors with Imatinib resulted in a significant decrease
of dividing progenitors16. In the in silico experiment, treatment with
Imatinib, simulated by reducing the base constant of Bcr-Abl from 2
to 1 results in a decrease of the ‘‘proliferation’’ cell fate from 2 to 1.
The other four successfully replicated experiments included the
observations that MEK-ERK activation of HNRPK is not required
for cytokine independent proliferation, that Interleukin-3 (IL-3)
upregulation induces factor independent growth in leukemic cells,
that Bcl-XL suppression induces apoptosis in CML cells, and that
Bcr-Abl conveys the ability for CML cells to have factor-independent
growth17–20. Experimental results were not exactly duplicated in one
Table 2 | Outcomes of double knock-out experiments. Summary of possible outcomes of double knock-out experiments. For each outcome
(i.e., levels of growth arrest, self-renewal, apoptosis, proliferation, and differentiation) we list the number of double knock-outs that produce
this outcome (repetitions) and one example of such pairwise knock-out
growth arrest self renewal apoptosis proliferation differentiation #repetitions KO1 KO2
Wild-type 0 1 1 0 0 2 CEBPA cMyc
1 1 1 0 0 2 cMyc Fli-1
0 1 0 1 0 4 Fli-1 FoxO
0 0 1 1 0 10 Stat3 Fli-1
0 1 1 1 0 79 CEBPA TCR
1 0 1 0 1 21 HNRPK IL-6 R
1 1 1 0 1 83 ERK HNRPK
0 0 0 1 1 6 FoxO IL-6 R
0 1 0 1 1 71 PI3K Bim/FasL
0 0 1 1 1 210 IL-6 R Jun
0 1 1 1 1 737 JunB TCR
Chronic Phase 0 1 0 0 0 2 cMyc Jun
1 1 0 0 0 2 Ras cMyc
0 0 0 1 0 8 JAK2 Jun
0 1 0 1 0 314 IL-6 R Jun
1 1 0 1 0 8 MEK cMyc
0 0 1 1 0 8 Stat5 CrkL
0 1 1 1 0 16 IL-3 R CrkL
0 0 0 2 0 38 IL-6 R JAK2
0 1 0 2 0 702 IL-6 R TCR
0 0 1 2 0 42 Stat5 TCR
0 1 1 2 0 38 Bcl-xL Frizzled
1 1 1 0 1 2 Bcr-Abl cMyc
0 1 0 1 1 2 Bcr-Abl FoxO
0 0 1 1 1 5 Bcr-Abl IL-6 R
0 1 1 1 1 38 Bcr-Abl TCR
Blast Crisis 0 2 0 0 0 2 cMyc Jun
1 2 0 0 0 2 Ras cMyc
0 1 0 1 0 36 Hck Jun
0 2 0 1 0 286 JunB IL-6 R
1 2 0 1 0 8 Ras cMyc
0 1 1 1 0 10 cMyc Stat5
0 2 1 1 0 14 IL-3 R CrkL
0 0 0 2 0 1 JAK2 BCat
0 1 0 2 0 154 IL-6 R Hck
0 2 0 2 0 585 IL-6 R TCR
0 0 1 2 0 1 Stat5 BCat
0 1 1 2 0 44 Bcl-xL BCat
0 2 1 2 0 35 Bcl-xL IL-6 R
1 1 1 0 1 2 Bcr-Abl cMyc
0 1 0 1 1 2 Bcr-Abl FoxO
0 0 1 1 1 5 Bcr-Abl IL-6 R
0 1 1 1 1 38 Bcr-Abl TCR
www.nature.com/scientificreports
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case concerning a study byUchida et al., who had observed that EPO-
mediated reduction of apoptosis is increased by Imatinib as
measured by Annexin V staining and FACS21. In the in silico
experiment, decreasing EPO from its base level of 2 to 1 resulted in
the model remaining at the baseline. A manual inspection of the
model under each of these conditions showed that the levels of
individual proteins associated with apoptosis were increased. The
individual changes however were insufficient to alter the global
‘‘apoptosis’’ aggregator behavior. We therefore conclude that the
model accurately reproduces the behavior of individual apoptotic
pathways but that the change is small relative to the overall
granularity of the cell behavior. This apparent difference may
reflect either the model itself, or the specific sensitivities of the
different experiments used to determine the activity of apoptotic
pathways.
Simulation of combinatorial gene knock-outs identifies concurrent
targeting of Ras and Bcl-xL as a potential strategy to restore normal
behaviour in CP CML while limiting negative effects on normal
cells. Having demonstrated faithful reproduction of known
experimental phenotypes, we next set out to analyze phenotypes
following systematic network perturbations. A knock-out of a
node in the QN represents the reduction of activity of a protein
through non-specific inhibition of the protein activity. For
example, Imatinib action represents one possible type of node
knock out, as it reduces the kinase activity of Bcr-Abl for all its
phosphorylatable substrates. Combinatorial therapy has been
identified as a powerful technique for treating diseases whilst
minimizing the opportunities for drug resistance and side
effects22,23. It is used therapeutically in diverse diseases, including
hypertension24, breast cancers25 and diabetes26. Furthermore,
theoretical approaches have been shown previously to be a
valuable approach, both for identifying useful combinations and
testing a models validity27,28. We initially focused on all possible
pairwise knock-outs of genes. The results are summarized in
Table 2 and Supplemental Table 4. Knock-outs of genes were
simulated by restricting the range of the gene to a single value 0.
Notably, the single knock-out pair, Ras and Bcl-xL, resulted in the
restoration of CP-CML cells to a near-normal state (apoptosis back
to normal level of 1) without negatively affecting the WT behavior
(all cell fate/behaviors remained at the non-KO baseline levels). In
both the CP-CML state and the BC-CML state, the most prevalent
effect of a pairwise KO is to remain at their baseline levels, thus
indicating that even during the chronic phase, CML represents a
robust cellular state, where multiple redundancies in growth and
survival pathways allow for the spread and survival of diseased cells.
CP CML and BC CML resist pairwise removal of gene interactions.
Similar to the network perturbations with the pairwise knock-outs of
entire gene nodes, we next analyzed pairwise KOs of interaction
edges. In contrast to knock-outs of whole nodes, these represent
the disruption of specific interfaces between different genes or
proteins. A real-world therapeutic example (taken from a different
system) of such an effect would be the disruption of the p53-MDM2
interface by Nutlin compounds. Knock-outs of interactions were
simulated by setting the value of the specific edge to 0. As
summarized in Supplemental Table 5, out of a total of 6240
perturbations that do not alter an edge directly connected to a
fate, only five pairs of interaction KOs showed an increase of
growth arrest alongside a reduction of proliferation in either the
CP CML or the BC CML states. For the KOs of IL3 to IL3R and
Bcr-Abl to CrkL, proliferation was reduced in the CP CML state and
apoptosis induced, consistent with results found by Seo et al29.
Proliferation was slowed in the BC CML state from 2 to 1 and
apoptosis increased to 1, but otherwise remained the same as the
baseline BC CML. For the KOs of Bcr-Abl to Abi1 and Abi2 and
Bcr-Abl to CrkL, WT cells remained at their baseline cell behaviors,
while CP CML cells reduced both proliferation and self-renewal
capacity levels to 1 (but apoptosis remained at 0) and BC CML
cells reduced the proliferation (and had apoptosis at 0).
Collectively, the results of Supplemental Table 5 are again
consistent with significant stability of the CP-CML and BC-CML
regulatory states as all are found to be stable. For the KOs of Bcr-
Abl to CrkL and Bcr-Abl to Pag, WT cells remained at the normal
baseline behavior, while CP CML cells reduced both proliferation
and self-renewal capacity levels to 1 (with apoptosis remaining at 0)
and BC CML cells reduced proliferation level to 1 (with apoptosis
remaining at 0).
CP CML and BC CML may lose sensitivity to interleukin-6,
erythropoietin and growth hormone in comparison to the WT
population. In a further set of in silico experiments, we next
explored the consequences of changing the levels of external
factors. Factor levels were varied between 0 and 2 in all possible
combinations in the models describing WT cells, CP CML, and BC
CML. Growth factor removal was simulated by restricting the range
of the factor from 0 to 0, essentially setting the target function to a
constant 0. InWT cells, it was found that removal of IL-6 resulted in
low self-renewal capacity (0). Pairwise removals of IL-3 with either
EPO or GH resulted in growth arrest (1), and low self-renewal
capacity and proliferation (0). Removal of EPO and GH together
lead to a reduction in self renewal (0). In contrast, in both the CP
CML and BC CML states, interestingly only IL-3 removal (with or
without removal of EPO and GH) had any effect on cell behavior,
resulting in a reduction in proliferation from 2 to 1. This is consistent
with previous work by Otsuka et al. indicating that IL-3 can enhance
the proliferation of early human hematopoietic cells30. These results
seem to be in agreement with the consensus in literature that as the
disease progresses, cells lose their reliance upon external factors for
growth and survival, and instead are driven by Bcr-Abl and the
aberrantly-stimulated downstream pathways.
Imatinib inhibition of Bcr-Abl partially restores the healthy state..
We simulated Imatinib inhibition of Bcr-Abl by reducing the
constant in the target function of Bcr-Abl from 2 to 1 (as
illustrated in Figure S2). This leads to the model becoming
unstable. In this case, instability is associated with the cellular
model remaining in a diseased state, but the opposite, where
stability is associated with a disease state and instability a shift
toward a normal phenotype, is seen in the results described by
Holtz et. al. in 2002 where treatment with Imatinib reduces
proliferation of progenitor cells16. In addition to the expected drop
in the Proliferation phenotype node from 2 to 1, the Apoptosis and
Correct Differentiation nodes shift from the stable values of 0 to
oscillating between values 0 and 1, illustrating that stabilization
does not necessarily correspond with the ‘‘normal’’ or ‘‘correct’’
phenotype.
Combined treatment with Imatinib and a Bcl Family Member
Inhibitor mostly restores normal behaviour in the CP CML
state without negatively affecting the behaviour of WT cells.
Finally, as a brief survey of possible chemotherapeutic options of
Imatinib and inhibitors currently available, combinations of
‘‘Imatinib treatment’’ (setting the base Bcr-Abl level to 1) with
inhibition of several combinations of genes known to have
functioning inhibitors were performed. A total of 175 simulations
were performed. Of these, only the Imatinib and pan-Bcl2 family
gene inhibitor combination described by Meng et al. and Goff et
al. restored the normal phenotype in the CP CML state without
changing the WT population from the baseline state31,32. Bcl2
family gene inhibition was simulated through fixing Bcl-2, Mcl-1L
and Bcl-xL levels to 1. At this state, proliferation and self-renewal
capacity decreased to 1 and apoptosis increased to 1. However,
correct differentiation fluctuated between 0 and 1. This result is
www.nature.com/scientificreports
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illustrated in Figure 3. In BC CML, the same combination of
‘‘Imatinib treatment’’ and inhibitions shows variable efficacy. This
variability is broadly consistent with patient response to treatment
with Imatinib, where benefits were seen in the short term but long
term prognosis remains unsatisfactory33. Taken together therefore,
comprehensive in silico perturbations highlighted the relative
stability of CML regulatory states, and also identified several new
leads for the development of new therapeutic strategies.
Discussion
In this study, we constructed and analyzed a genetic model of CML
and its progression to the most aggressive blast crisis state using a
new biologist-friendly tool for Qualitative Network modeling
(BMA). The validity of the model was verified through replicating
in silico experimental data not utilized in the construction of the
model. New combinations of druggable genes were predicted, and
a novel mechanistic hypothesis was formed that a fundamental dif-
ference may exist between modulating combinations of genes and
combinations of genetic interactions. This study not only offers new
insight into CML, but has much wider application in the necessary
development of suitable data interpretation and modeling tools,
which lags behind the corresponding production of complex datasets
ubiquitous across virtually all areas of biomedical research. One of
the most promising arenas for computational modeling is the field of
drug discovery. Because drugs are typically given systemically, reduc-
tionist approaches are unsuitable predictors of a drug’s effect on the
entire system34. We elected to develop a network model encapsul-
ating the known biology of CML as the first large real-world applica-
tion of BMA. This approach had the advantages that (1) CML is
genetically tractable because of the uniform initiating translocation
event, (2) there is a large body of literature on the genetic pathways
relevant for CMLbiology, and (3) a networkmodel for CML afforded
us an opportunity to evaluate the potential utility of modeling using
BMA within the context of drug discovery. Importantly, our model
showed excellent agreement with known experimental data that were
not utilized for its construction. All seven of the experimental results
tested that were not used in the construction or refinement of the
model essentially agreed with the in silico predictions produced.
Similar modeling of gene regulatory networks, and indeed even a
leukemicmodel, using BooleanNetworks have been performed prev-
iously by Saadatpour andWang in the Albert lab35. However, the use
of Qualitative Networks and thus the expansion to multiple possible
states past the binary restriction of Boolean Networks, as well as
ability to integrate multiple inputs and describe more complex rela-
tions using target functions explains the greater agreement of model
results with experimental data. This degree of accuracy motivated us
to perform extensive perturbation analysis which resulted in several
noteworthy observations as discussed below.
The lack of detectable cell behavior changes from both the whole
gene and gene interaction double KOs was surprising. Though it is
Figure 3 | Drug simulation through fixing representative node values. Drug simulation through fixing representative node values. In this model,
drugging of the base CP CMLmodel previously illustrated in Figure 2 is simulated by reducing the constant value portion of Bcr-Abl from 2 to 1 (the in
silico Imatinib treatment), and preventing Bcl2,Mcl1L, and BclXL from fluctuating to the high level of 2 by fixing these nodes at a constantmoderate level
of 1 (the in silico pan Bcl2 family member inhibitor treatment). Corresponding changes in phenotype value are illustrated on the right.
www.nature.com/scientificreports
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perhaps not unexpected that even a genetically relatively ‘‘simple’’
malignancy such as CMLwill havemultiple, at least partially redund-
ant pathways promoting growth and survival, our model of 54 nodes
and 104 interactions pared down many pathways to the canonical
genes. Therefore, even though the model was complex by compar-
ison to other models in the literature, one would have expected that
with such a core set of genes, more genes would be essential for
function. Our analysis however suggests that the CML regulatory
state is extremely robust, requiring multiple perturbations to elicit
changes in cellular behavior that reconfigure CML cellular states
towards a more wild type configuration. In some sense, this result
confirms the necessity of a systems biology approach, because it
seems reasonable to conclude that other cancers which are associated
with many more genetic alterations may require even more complex
interventions where it would be virtually impossible tomake rational
predictions on combinatorial perturbations without the aid of
advanced modeling approaches.
Another interesting observation providing potential new mech-
anistic insight is the finding that different genes within the CML
regulatory network are critical in cell behavior depending onwhether
whole genes (network nodes) or just gene-gene interactions (network
edges) are removed. The only gene pair showing a disease reversal
phenotype in the pairwise network node removal was Bcl-xL, an anti-
apoptotic gene, and Ras, a gene upstream in the MAP kinase path-
way, yet neither of these genes was present in the gene pairs with
phenotype reversal following pairwise network edge removal. Of
note, Bcl-xL occupied an endpoint location within the network,
and only had one interaction with any other gene in the network.
Since removal of the edge to Bcl-xL would be equivalent to removing
Bcl-xL altogether, our data highlight the potential to generate differ-
ent phenotypes with node and edge removals, because none of the
other edges, when removed, could generate the same phenotype that
was seen following the pairwise edge removal of Bcl-xL and Ras. The
potential to generate distinct phenotypes by targeting network nodes
and edges enhances the scope for pharmacological intervention sig-
nificantly, particularly since recent drug development programs have
successfully targeted specific protein-protein interactions in addition
to the more conventional total inhibitor drugs36,37. Importantly, the
BMA model of CML introduced here provides a platform that facil-
itates the interrogation of potential phenotypes following combin-
atorial interventions that can be a complex mixture of drugs that
target network nodes and/or edges.
While several of the key genes and genetic interactions found were
obvious (such as the removal of Bcr-Abl’s repression of its own
repressors), others were novel. The pairwise gene KO of IL3R and
Bcl-xL for example was unusual in the combination of a broad,
upstream and a terminally-downstream gene. Gene interaction ana-
lysis also highlighted CrkL as a critical gene in the survival and spread
of CML, indicating its significance in Imatinib-resistant CML
beyond its current usage as only a predictor of clinical outcome
and as a potential druggable target.
We have chosen BMA and Qualitative Networks for the elabora-
tion of our model. BMA’s unique feature is that it makes the con-
struction of an initial model extremely simple, allowing users with no
prior experience to start work immediately and produce preliminary
models38,39. It supports analysis techniques that are based on formal
verification and techniques that were developed in the formal veri-
fication community to represent and analyze large state spaces13.
Thus, BMA offers the ability to analyze very large networks. BMA
gives up a priori the attempt to draw the explicit state graph, as this is
infeasible even for moderately sized models. At the same time, the
interface does allow using the more complex features of Qualitative
Networks8 and allows an advanced user to create advanced models.
We are currently adding more support for additional types of ana-
lysis. The successful implementation of BMA in this study highlights
its utility as a powerful tool for systems-level computational model-
ing and subsequent analysis, with applicability across a wide range
biomedical research fields.
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